Page 109 - ADULT-ONSET ASTHMA PREDICTORS OF CLINICAL COURSE AND SEVERITY

Table 3. Patients with Asthma Persistence, with and without Nasal Polyps.
CLINICAL PREDICTORS OF REMISSION AND PERSISTENCE OF ADULT-ONSET ASTHMA
Absence of nasal polyps (n=107)
65
48 ±14 28.5 ±5.4
53
2 (0-14)
Nasal polyps (n=35)
nn
p-value
Gender, % female Age, years
BMI, kg/m2 (Ex)smoker, % Pack years
107 29 107 56 107 27.2 107 71 106 8 100 1.12 107 85 107 69 105 0 107 500 107 94
104 89 102 106 107 99 107 109 104 5 107 92 107 105 101 93
98 2.5
NA 66 99 100 107 29 106 49 107 20
101 79 101 39 103 3.8 103 0.26
±14 ±4.9
(0-18) ±0.81
(250-500)
±20
±18
±19
±17 (3-11) ±12
±15
±21 (0.5-10.6)
(30-240) (19-68) (3.3-4.3) (0.2-0.35) (0.9-8.9) (33-79)
35 <0.001 35 0.004 35 0.225 35 0.059 35 0.132 33 0.133 34 0.450 35 0.463 32 0.262 34 0.489 34 0.632
31 0.152 29 0.985 35 0.707 35 0.726 34 0.143 35 0.056 35 0.004 32 0.137 32 0.944
35 NA 35 <0.001 35 0.155 35 0.465 35 0.058
34 0.396 34 <0.001 35 0.994 35 <0.001 21 0.001 21 0.188
ACQ-6 score
Inhaled corticosteroid (ICS) use, %
ICS and second controlller, %
Oral corticosteroid use, % 4
ICS dose (fluticasone equivalent) Any asthma medication baseline, %
pre FEV1 % predicted
pre FVC% predicted
post FEV1 % predicted
post FVC% predicted
FEV1 % reversibility
post FEV1/FVC% predicted Post DLCOcVA % predicted post RV/TLC ratio % predicted PC20-Metacholine, mg/ml
Nasal polyp surgery, % CRS, %
GERD, %
Atopy, %
Obesity, %
Total IgE, kU/L
FeNO, ppb
Blood neutrophils, 109/L Blood eosinophils, 109/L Sputum eosinophils, % Sputum neutrophils, %
62
250 (125-500) 92
94 ±16 105 ±16 100 ±16 108 ±16
5 (2-8) 96 ±11 96 ±15 87 ±19
2.8 (0.9-6.4)
NA 44 42 42 37
60 (23-229) 16 (13-31) 3.7 (2.9-4.8) 0.16 (0.1-0.24)
1.40 ±0.94 79
0.4 (0.1-1.6) 65 2.3 72 (52-86) 65 68
Pre: pre-bronchodilator. Post: post-bronchodilator. GERD: gastroesophageal reflux (±SD), median (interquartile range) or percentage.
3
disease. Data are
presented as mean
107